

Strategic partnerships to provide unique solutions

Barc Lab is dedicated to advancing healthcare. It does so by offering customised solutions for its clients, and it consciously chooses a partnership model that can help its clients to optimise their clinical trial process.

Pharmaceutical and biotech companies are dealing with a paradigm shift in drug development as the industry embraces more personalised, complex and expensive cell therapies. With some therapeutics proving ineffective in as many of 75% of patients, the need for precision medicine is clear, as is the benefit of using selection biomarkers in the drug development process where success rates can triple. Consequently, companies are balancing the increased demands for unique, esoteric testing with budget restrictions and geographical coverage.

In the quest to accelerate drug discovery to market and reduce costs, the industry continues ever further with externalisation and outsourcing of drug development. Outsourcing penetration is expected to expand, as pharmaceutical and biotech companies must continue to replenish their pipeline and, hence, are incessantly looking for new sources of innovation.

“With 42% of all drugs in development classified as personalised medicine, rising to 73% for oncology, the industry is being challenged to keep pace with this ongoing change. Barc Lab, being a central laboratory, is continuing to evolve to meet with the challenges posed by the increasingly complex clinical trial environment.”

Shift gears

With 42% of all drugs in development classified as personalised medicine, rising to 73% for oncology, the industry is being challenged to keep pace with this ongoing change. Barc Lab, being a central laboratory, is continuing to evolve to meet



XX

with the challenges posed by the increasingly complex clinical trial environment. Over the past decade, the industry has seen a marked shift in the mainstay of central labs' functionality by the addition of testing biomarkers next to diagnostics, always keeping an eye on the end deliverable – demonstrating the safety and efficacy of a drug or treatment.

With the era of personalised and precision medicine, Barc Lab has expanded its portfolio beyond the routine safety and efficacy parameters in order to deliver value. It is embracing this challenging shift and committing to providing a full repertoire of next-generation assays.

Team up – bridge the gap in expertise and knowledge

The biomarker demand is so dynamic that it can feel like every week a new assay emerges, sometimes with a focus on a single biomarker. The pace of innovation is relentless and shows no sign of abating. These innovator labs need to leverage profound knowledge and therapeutic expertise to provide a refined and agile approach to managing trial complexity.

Barc Lab employs a highly flexible business model that enables external innovation through bringing in trusted partners who can address gaps in certain niches, such as next-generation sequencing and the expanding fields of omics.

Barc Lab's experience has shown that the optimal approach is to partner with a lab that can demonstrate the right expertise required instead of investing a big amount of money in infrastructure, equipment and experts. In this way, Barc Lab's clients can be confident they are getting the right science and capabilities at the right time to help drive drug

